First Ulcerative Colitis Patients Dosed in Phase 2a Trial of TopiVert’s New Therapy

First Ulcerative Colitis Patients Dosed in Phase 2a Trial of TopiVert’s New Therapy
The first patients have been dosed in TopiVert’s Phase 2a trial to assess the effectiveness, safety, and tolerability of TOP1288 (rectal form) for moderate to severe symptomatic ulcerative colitis. TopiVert focuses on developing narrow spectrum kinase inhibitors (NSKIs) into new locally-acting drugs to treat chronic inflammatory diseases of the gastrointestinal (GI) tract and eye. TOP1288, the company’s lead candidate for ulcerative colitis (UC),

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *